A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo Mgodi, Erica Lazarus, Precious Garnett et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 45
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly Karuna et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 26
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized TrialsSimbarashe Takuva, Shelly Karuna, Michal Juraska et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 11
Infusion Reactions in Persons Receiving the Broadly Neutralizing Antibody VRC01 or Placebo for Reduction of HIV-1 Acquisition: Results From the Phase 2b Antibody Mediated Prevention (AMP) Randomized TrialsSimbarashe Takuva, Nyaradzo Mgodi, Shelly Karuna et al.|SSRN Electronic Journal|2021Cited by 0